List of Orfadin drug patents
Orfadin is owned by Swedish Orphan.
Orfadin contains Nitisinone.
Orfadin has a total of 1 drug patent out of which 0 drug patents have expired.
Orfadin was authorised for market use on 22 April, 2016.
Orfadin is available in suspension;oral dosage forms.
Orfadin can be used as treatment of hereditary tyrosinemia type 1 (ht-1) in combination with dietary restriction of tyrosine and phenylalanine.
The generics of Orfadin are possible to be released after 28 February, 2033.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9301932 | SWEDISH ORPHAN | Liquid pharmaceutical composition comprising nitisinone |
Feb, 2033
(10 years from now) | |
Drugs and Companies using NITISINONE ingredient
Market Authorisation Date: 22 April, 2016
Treatment: Treatment of hereditary tyrosinemia type 1 (ht-1) in combination with dietary restriction of tyrosine and phenylalanine
Dosage: SUSPENSION;ORAL
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic